15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $317M | 83.6% | 33.6% | 649.2% | 12.5% | $645M | $2.1B | $134M |
| 2024 | $1.0B | $444M | 84.3% | 54.3% | 122.1% | 21.5% | $468M | $1.5B | $116M |
| 2023 | $829M | $282M | 76.8% | 40.7% | 336.0% | 16.2% | $373M | $1.5B | $118M |
| 2022 | $660M | $202M | 78.9% | 40.5% | 119.0% | 11.0% | $235M | $1.5B | $234M |
| 2021 | $443M | $403M | 81.6% | 62.2% | 204.5% | 36.5% | $298M | $787M | $119M |
| 2020 | $268M | $129M | 83.8% | 53.9% | 85.5% | 22.3% | $53M | $0 | $148M |
| 2019 | $196M | -$72M | 76.8% | -34.5% | -78.7% | -12.8% | -$89M | $383M | $120M |
| 2018 | $152M | -$80M | 93.3% | -45.7% | -32.3% | -18.2% | -$54M | $35M | $58M |
| 2017 | $317M | $63M | 90.2% | 25.6% | 30.2% | 12.1% | $133M | $125M | $169M |
| 2016 | — | -$103M | — | — | 317.2% | -39.4% | -$54M | $199M | $67M |
| 2015 | — | -$32M | — | — | -75.0% | -17.7% | -$39M | $28M | $43M |
| 2014 | — | -$68M | — | — | -165.3% | -41.2% | -$49M | $50M | $61M |
| 2013 | — | -$83M | — | — | 417.6% | -82.0% | -$52M | $50M | $27M |
| 2012 | — | -$54M | — | — | -109.6% | -39.7% | -$66M | $30M | $100M |
| 2011 | — | -$20M | — | — | -181.4% | -30.1% | -$35M | $0 | $52M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $481M | $230M | 83.5% | 59.8% | 160.2% | 8.9% | $237M | $2.1B | $163M |
| Mar '26 | $377M | $150M | 79.0% | 49.0% | 68.3% | 5.6% | $176M | $2.1B | $310M |
| Dec '25 | $452M | -$142M | 82.6% | -20.6% | -290.1% | -5.6% | $218M | $2.1B | $134M |
| Sep '25 | $354M | $175M | 84.4% | 61.5% | 34.8% | 7.9% | $176M | $1.5B | $420M |
| Jun '25 | $326M | $165M | 85.8% | 62.2% | 49.6% | 8.0% | $98M | $1.5B | $62M |
| Mar '25 | $265M | $118M | 81.7% | 53.4% | 24.5% | 5.4% | $153M | $1.5B | $176M |
| Dec '24 | $298M | $137M | 85.9% | 58.9% | 37.7% | 6.6% | $175M | $1.5B | $116M |
| Sep '24 | $290M | $137M | 83.0% | 56.3% | 30.3% | 6.5% | $114M | $1.5B | $154M |
| Jun '24 | $231M | $93M | 82.9% | 50.7% | 32.2% | 4.7% | $53M | $1.5B | $188M |
| Mar '24 | $196M | $77M | 85.5% | 48.8% | 43.2% | 4.2% | $126M | $1.5B | $165M |
| Dec '23 | $230M | $85M | 77.3% | 43.9% | 101.9% | 4.9% | $100M | $1.5B | $118M |
| Sep '23 | $216M | $82M | 74.6% | 40.9% | 32.8% | 4.3% | $129M | $1.5B | $274M |
| Jun '23 | $221M | $75M | 77.3% | 42.7% | 49.5% | 4.1% | $68M | $1.5B | $221M |
| Mar '23 | $162M | $40M | 78.3% | 33.2% | 60.2% | 2.3% | $76M | $1.5B | $96M |
| Dec '22 | $181M | $58M | 76.8% | 41.1% | 34.0% | 3.1% | $80M | $1.5B | $234M |
| Sep '22 | $209M | $62M | 77.4% | 39.9% | 63.5% | 3.3% | $69M | $1.5B | $147M |
| Jun '22 | $152M | $23M | 77.7% | 22.4% | 7.7% | 1.3% | $39M | $1.1B | $91M |
| Mar '22 | $117M | $60M | 86.4% | 64.5% | 23.1% | 5.2% | $47M | $788M | $118M |
| Dec '21 | $102M | $67M | 78.8% | 55.4% | 33.9% | 6.0% | $82M | $787M | $119M |
| Sep '21 | $116M | $217M | 84.0% | 65.3% | 76.9% | 18.3% | $121M | $786M | $492M |
How the market has priced HALO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Halozyme Therapeutics, Inc.'s revenue has grown 39.2% per year, and net income grown 19.7% per year. These are computed facts, not advice.
As of FY2025, Halozyme Therapeutics, Inc. reported $2.1B of total debt against $134M of cash; operating income covered interest expense 26×.
In FY2025, gross margin was 83.6%, operating margin 33.6%, and net margin 22.7%.
As of Sep '26, Halozyme Therapeutics, Inc. traded at a price-to-earnings ratio of about 39.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.